Semaglutide vs Tirzepatide: Mechanisms, Outcomes, and the Compounding Pharmacy Landscape

Semaglutide and tirzepatide have reshaped pharmacological weight management. Both are injectable compounds approved by the FDA. Both work through incretin hormone pathways. And both have been offered through compounding pharmacies — with a regulatory landscape that continues to shift. Here is a clear comparison.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that mimics glucagon-like peptide-1, an incretin hormone produced in the gut after eating. It is FDA-approved under two brand names:

• Ozempic (2.0 mg/week max) — approved for type 2 diabetes management
• Wegovy (2.4 mg/week) — approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related condition

Its mechanism involves three primary actions: stimulating glucose-dependent insulin secretion, suppressing glucagon release to reduce liver glucose output, and — critically for weight management — slowing gastric emptying and activating GLP-1 receptors in the hypothalamus to reduce appetite and caloric intake.

Semaglutide has a half-life of approximately seven days, achieved through structural modifications including a C18 fatty diacid chain that enables reversible albumin binding.

What Is Tirzepatide?

Tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. It is FDA-approved as:

• Mounjaro — approved for type 2 diabetes
• Zepbound — approved for chronic weight management

The addition of GIP receptor agonism adds a complementary mechanism. GIP independently enhances insulin secretion and modulates adipose tissue metabolism through pathways distinct from GLP-1. The combined effect produces meaningfully greater average weight reduction in clinical trials.

Head-to-Head: What the Trial Data Shows

The SURMOUNT-5 trial (2025) provided the first direct randomised comparison of the two compounds at their maximum approved doses for weight management:

Outcome	Semaglutide 2.4 mg	Tirzepatide 10/15 mg
Mean weight reduction	~15% body weight	~20–22% body weight
Patients achieving ≥20% loss	~30%	~50%
Glycaemic improvement	Significant	Greater
Cardiovascular outcomes data	Established (SELECT trial)	Accumulating

Tirzepatide consistently achieves greater weight reduction on average. However, individual response varies substantially — some patients respond better to semaglutide, and tolerability profiles differ.

Side Effect Profiles

Both compounds share a class-effect side effect profile driven by GLP-1 receptor activity:

Common: Nausea, vomiting, diarrhoea, constipation, reduced appetite. Most pronounced during dose escalation; typically attenuate over weeks.

Less common: Gastroparesis (delayed gastric emptying becoming pathological), pancreatitis, gallbladder disease.

Tirzepatide-specific: The GIP component may slightly reduce nausea incidence compared to semaglutide, though the evidence is mixed.

Contraindications (both): Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2. Both carry FDA black box warnings on this basis.

The Compounding Pharmacy Landscape

From 2022 through early 2025, compounded semaglutide and tirzepatide were widely available through 503A and 503B pharmacies in the United States. Compounding was legally permissible because both drugs were listed on the FDA's drug shortage list.

The regulatory shift: In early 2025, the FDA removed semaglutide from the shortage list and issued guidance that compounding of shortage-listed drug copies would no longer be permissible once a drug is off the list. Compounded tirzepatide followed later in 2025. This led to widespread enforcement activity against pharmacies and telehealth platforms offering compounded versions.

The current picture (2026): Compounding of bulk semaglutide and tirzepatide for routine weight management is significantly restricted. Some 503A pharmacies continue to offer compounded formulations for specific patient populations with documented clinical needs — for example, patients requiring specific doses not commercially available, or those with allergies to inactive ingredients. 503B outsourcing facilities face the strictest restrictions.

The branded versions (Wegovy, Zepbound) remain available through standard prescription channels, with manufacturer patient assistance programs for those without insurance coverage.

Finding Licensed Providers

Telehealth platforms and functional medicine clinics remain the primary access point for FDA-approved GLP-1 therapy under physician supervision. PeptideBase indexes providers that have publicly listed semaglutide and tirzepatide in their offerings.

• Semaglutide providers
• Tirzepatide providers
• Full provider directory

Always verify current regulatory status and prescription requirements with a licensed provider in your jurisdiction.

Comparison at a Glance

	Semaglutide	Tirzepatide
Mechanism	GLP-1 agonist	GLP-1 + GIP dual agonist
Brand names	Ozempic / Wegovy	Mounjaro / Zepbound
FDA weight approval	Yes (Wegovy)	Yes (Zepbound)
Average weight reduction	~15%	~20–22%
Cardiovascular outcomes trial	Established (SELECT)	Accumulating
Compounded availability (2026)	Heavily restricted	Heavily restricted
Injection frequency	Once weekly	Once weekly

Related Compounds

For patients seeking weight management support outside the GLP-1 pathway, AOD-9604 — a fragment of the growth hormone molecule — is researched for lipolytic properties with a different mechanism and a lower-risk profile.

---

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The regulatory landscape for compounded medications changes frequently — verify current status with a licensed prescriber before making any decisions.